Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Glenmark Pharmaceuticals
GLENMARK
Glenmark Pharmaceuticals
US Pricing Pressures And Regulatory Delays Will Dampen Performance
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
13 Jul 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹1,500.00
36.3% overvalued
intrinsic discount
16 Aug
₹2,044.60
Loading
1Y
25.3%
7D
-0.2%
Author's Valuation
₹1.5k
36.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹1.5k
36.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-16b
183b
2014
2017
2020
2023
2025
2026
2028
Revenue ₹183.2b
Earnings ₹29.5b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.50%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹29.53b
Earnings '28
x
20.52x
PE Ratio '28
=
₹605.95b
Market Cap '28
₹605.95b
Market Cap '28
/
282.99m
No. shares '28
=
₹2.14k
Share Price '28
₹2.14k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹1.49k
Fair Value '25